CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced that Richard T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview and update on the Company’s oncology pipeline at the BIO CEO & Investor Conference on Tuesday, February 14th at 3:00 pm at The Waldorf-Astoria Hotel in New York. Dr. Robert L. Capizzi, M.D., F.A.C.P., Senior Vice President and Chief Medical Officer, will participate in the Revisiting Cytotoxics with New Molecules Focus Session scheduled on Tuesday, February 14th at 9:00 am, also at the Waldorf-Astoria Hotel. A live audio webcast of the presentation will be available on the Company’s website located at http://www.xanthus.com. A replay of the presentation will be posted on the Xanthus website approximately thirty minutes after the event.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical- stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. - kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences, Inc. - john.mccarthy@xanthus.com or (617) 225-0522, x 125
Xanthus Life Sciences, Inc.
CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc.,+1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr., SeniorVice President & CFO of Xanthus Life Sciences, Inc., +1-617-225-0522, ext.125, john.mccarthy@xanthus.com
Web site: http://www.xanthus.com/
